{"id":"NCT01171976","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Ranibizumab in Two \"Treat and Extend\" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus","officialTitle":"A 2 Year Randomized, Single-masked, Multicenter, Controlled Phase IIIb Trial Assessing the Efficacy and Safety of 0.5 mg Ranibizumab in Two \"Treat and Extend\" Treatment Algorithms vs. 0.5 mg Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2013-04","completion":"2013-04","firstPosted":"2010-07-29","resultsPosted":"2014-09-15","lastUpdate":"2014-09-15"},"enrollment":373,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Macular Edema"],"interventions":[{"type":"DRUG","name":"Ranibizumab","otherNames":[]}],"arms":[{"label":"TE Ranibizumab 0.5 mg and Laser","type":"EXPERIMENTAL"},{"label":"TE Ranibizumab 0.5 mg alone","type":"EXPERIMENTAL"},{"label":"PRN Ranibizumab 0.5 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to demonstrate that two investigational treatment regimens have the potential to result in a superior visual acuity improvement as compared to a ranibizumab pro re nata (PRN=as needed) treatment regimen.","primaryOutcome":{"measure":"Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12","timeFrame":"Baseline to Month 12","effectByArm":[{"arm":"TE Ranibizumad 0.5 mg and Laser","deltaMin":62.3,"sd":11.5},{"arm":"TE Ranibizumab 0.5 mg Alone","deltaMin":64.1,"sd":10.52},{"arm":"PRN Ranibizumab 0.5 mg","deltaMin":65.1,"sd":10.08}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":13},"locations":{"siteCount":68,"countries":["Belgium","Czechia","France","Greece","Hungary","Ireland","Italy","Netherlands","Poland","Portugal","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["26453639"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":126},"commonTop":["Hypertension","Nasopharyngitis","Influenza","Urinary tract infection","Conjunctival haemorrhage (Study eye)"]}}